Roundup Cancer Lawsuit News

Bayer's Financial Involvement In Glyphosate Research Could Be A Conflict Of Interest

Bayer funding research into glyphosate cancer could delay trials for many years

Tuesday, June 30, 2020 - Bayer/Monsanto attorneys have adopted a strategy that could minimize an alleged glyphosate victim's ability to sue the company going forward or at least delay justice for years. The latest iteration of the Bayer/Monsanto, Roundup herbicide/cancer settlement consists of payments of around 10 billion dollars divided according to pre-agreed upon terms among 95,000 plaintiffs. The payout leaves 30,000 lawsuits pending court appearances, dates that Monsanto attorneys would love to see postponed indefinitely. The agreement stipulates that $1.25 billion set aside to fund research that could settle the argument once and for all whether or not glyphosate, the active ingredient in Roundup, causes cancer and whether or not the chemical compound that makes up Roundup is hazardous to human health. Bayer/Monsanto attorneys failed to admit guilt in the settlement's terms and will not be required to place a cancer warning label on the weedkiller. Roundup herbicide cancer attorneys are national lawyers with a winning track record litigating against big corporations and offer a free consultation.

The $10 billion will allow the Bayer to move forward with business as usual and will placate stockholders furious over its 2018 acquisition of Monsanto in the first place. Bayer stockholders forced the retirement of the Bayer CEO responsible for the Monsanto deal in a vote of no confidence. Bayer hopes to have cleared the slate and delay the 30,000 pending lawsuits until the results of the scientific studies which, Bayer hopes will take years to conclude if ever. The longer Bayer can delay the results, the longer they can delay the lawsuits.

Legal experts agree, however, that relying on Bayer/Monsanto to fund and administer glyphosate cancer testing is like a fox watching over a hen house. The research may fall into the same trap Monsanto set for scientific research in the past. In documents entitled The Monsanto Papers, researchers found that Monsanto has a history of manipulating scientific test data to give the impression that the glyphosate test results were independent and legitimate as well as a history of coercing FDA officials. Much of this evidence finally made it to the jury, however, in the Pilliod trial. Michael Miller, co-counsel for the plaintiffs, told US Right to Know, "we were finally allowed to show a jury the mountain of evidence showing Monsanto's manipulation of science, the media, and regulatory agencies to forward their agenda despite Roundup's severe harm to the animal kingdom and humankind."

Attorneys that represent the 30,000 pending lawsuits that claim that glyphosate the active ingredient in Roundup herbicide causes cancer are adamant that trials against the company continue without delay. In a recent article in The Insurance Journal, attorneys noted that 30,000 cases refused to settle, "... and the number of cases is growing. Last week, attorney Fletch Trammell filed 13 suits on behalf of kids who developed non-Hodgkin's lymphoma after being exposed to the weedkiller in backyards, parks, and playgrounds." Prior lawsuits were on behalf of occupational users that developed cancer from using the herbicide during the course of their maintenance work on farms and government properties.

More Recent Roundup Cancer Lawsuit News:

Lawyers for Roundup Cancer Lawsuits

Attorneys handling Roundup cancer lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Roundup cancer lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Roundup cancer lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.